Marie-Louise VachonM.D., M.Sc., FRCP(C)

Onofrio FQ, Cooper C, Borgia SM, Vachon ML, Ramji A, Lilly LB, Wong A, Booth J, Sattar I, Morales H, Lee S, Conway B, Feld JJ

Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.

Clin Infect Dis, 72 (11), 2021.

Résumé | Liens:

Manion M, Lynn N, Pei L, Hammoud DA, Laidlaw E, Roby G, Metzger D, Mejia Y, Lisco A, Zelazny A, Holland S, Vachon ML, Scherer M, Bergin C, Sereti I

To Induce Immune Reconstitution Inflammatory Syndrome or Suppress It: The Spectrum of Mycobacterium genavense in the Antiretroviral Era.

Clin Infect Dis, 72 (2), 2021.

Résumé | Liens:

Cooper CL, Read D, Vachon ML, Conway B, Wong A, Ramji A, Borgia S, Tam E, Barrett L, Smyth D, Feld JJ, Lee S

Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants.

BMC Public Health, 20 (1), 2020.

Résumé | Liens:

Manion M, Lynn N, Pei L, Hammoud DA, Laidlaw E, Roby G, Metzger D, Mejia Y, Lisco A, Zelazny A, Holland S, Vachon ML, Scherer M, Bergin C, Sereti I

To Induce IRIS or Suppress It: The spectrum of Mycobacterium genavense in the antiretroviral era.

Clin Infect Dis, 2020.

Résumé | Liens:

Saeed S, Strumpf E, Moodie EEM, Wong L, Cox J, Walmsley S, Tyndall M, Cooper C, Conway B, Hull M, Martel-Laferriere V, Gill J, Wong A, Vachon ML, Klein MB, Barrett L, Cohen J, Côté P, Haider S, Montaner J, Pick N, Rachlis A, Rouleau D, Sadr A, Sanche S, Sandre R, Saskatchewan MBK

Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake Among People Living With Human Immunodeficiency Virus.

Clin Infect Dis, 71 (2), 2020.

Résumé | Liens:

Rossi C, Saeed S, Cox J, Vachon ML, Martel-Laferriere V, Walmsley SL, Cooper C, Gill MJ, Hull M, Moodie EEM, Klein MB

Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients.

AIDS, 32 (6), 2018.

Résumé | Liens:

Feld JJ, Ramji A, Shafran SD, Willems B, Marotta P, Huchet E, Vachon ML, Svarovskaia ES, Huang KC, Hyland RH, Yun C, Massetto B, Brainard DM, McHutchison JG, Tam E, Bailey R, Cooper C, Yoshida EM, Greenbloom S, Elkhashab M, Borgia S, Swain MG

Ledipasvir-Sofosbuvir Plus Ribavirin in Treatment-Naive Patients With Hepatitis C Virus Genotype 3 Infection: An Open-Label Study.

Clin Infect Dis, 65 (1), 2017.

Résumé | Liens:

Young J, Rossi C, Gill J, Walmsley S, Cooper C, Cox J, Martel-Laferriere V, Conway B, Pick N, Vachon ML, Klein MB

Risk Factors for Hepatitis C Virus Reinfection After Sustained Virologic Response in Patients Coinfected With HIV.

Clin Infect Dis, 64 (9), 2017.

Résumé | Liens:

Rolland S, Vachon ML

Sofosbuvir for the treatment of hepatitis C virus infection.

CMAJ, 187 (3), 2015.

| Liens:

Parikh ND, Martel-Laferriere V, Kushner T, Childs K, Vachon ML, Dronamraju D, Taylor C, Fiel MI, Schiano T, Nelson M, Agarwal K, Dieterich DT

Clinical factors that predict noncirrhotic portal hypertension in HIV-infected patients: a proposed diagnostic algorithm.

J Infect Dis, 209 (5), 2014.

Résumé | Liens: